Ebola virus from Mali blood sample
Infectious disease scientists report early development of a potential universal vaccine for Ebola viruses that preclinical tests show might neutralize all four species of these deadly viruses infecting people in recent outbreaks, mainly in Africa.
Although still in early preclinical testing, researchers report that their data indicate that the prospective vaccine has potential to be a stand-alone protection from Ebola. It also could broaden and extend the durability of protective immunity induced by current live vaccines already being tested in clinical trials against individual Ebola virus species, said Karnail Singh, PhD, the study’s co-principal investigator in the Division of Infectious Diseases.
“This could be a significant advancement in the global effort to prevent or manage Ebola outbreaks, especially if this vaccine used alone or in combination with another Ebola vaccine results in long-term and durable protective immunity against different Ebola viruses,” Singh said.
A deadly Ebola outbreak in West Africa between 2013 and 2016 accelerated international efforts to develop vaccines for these highly infectious and harmful viruses. This led to development of recombinant Ebola vaccines in which glycoprotein from Zaire Ebola virus is engineered into another modified live viral vector. When administered, these live vaccines induce immune responses against the Ebola glycoprotein that, in turn, protect against any subsequent attack by the Ebola virus.
Singh and colleagues report that while the live-vector vaccines are producing encouraging results in clinical trials, until the current study none of the new vaccines under development have been shown to induce immune responses that cross-react against multiple Ebola virus species that cause the deadly disease in humans.
A DIFFERENT APPROACH
The new vaccine takes a novel approach, according to the study. The researchers designed a bivalent, spherical Ebola virus-like particle (VLP) that incorporates two genetically diverse glycoproteins (one each from the Zaire Ebola virus and Sudan Ebola virus) on a spherical core. This approach will not cause illness in the recipient as the VLPs lack the genetic material and do not multiply. The vaccine works by stimulating immune responses against Ebola that generate virus-fighting antibodies to attack the different virus species.
When the researchers administered their new Ebola VLP vaccine to appropriate animal models, it produced robust immune responses against Ebola virus species known to be pathogenic in humans.
Although the new vaccine uses glycoproteins from two Ebola virus species, Singh said it might work against all four known pathogenic Ebola viruses as responses to one of the glycoproteins generates cross-reactive responses against two other Ebola virus species.
MORE TESTING NEEDED
The researchers emphasize that extensive additional preclinical testing of the prospective Ebola VLP vaccine is needed before it could potentially be tested in clinical trials.
A key collaborator on the multi-institutional study — which included the University of Cincinnati College of Medicine, the Emory University School of Medicine, and the University of Louisiana’s New Iberia Research Center – was Paul Spearman, MD, Director, Division of Infectious Diseases at Cincinnati Children’s.
Spearman said at the moment, vaccine challenge experiments are in the planning stages. They will involve working in collaboration with an institution that has Level 4 biosafety facilities and will require additional external funding to move this promising research forward.
“If the data from those studies is equally encouraging, the vaccine should be ready to progress to generation of clinical grade material for human trials,” he said.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Where We Stand on a Vaccine After Trump Catches COVID-19on October 2, 2020 at 12:58 pm
Major news broke Friday that President Trump and the First Lady tested positive for COVID-19 on Thursday night. This virus has proven pervasive from the lowest echelons of society to the highest ...
- Ebola responders face abuse allegations, COVID-19 vaccine funding, and Amnesty's battle with India: This week in developmenton October 1, 2020 at 1:42 pm
Sexual abuse allegations plague the Ebola response, the World Bank proposes $12 billion for COVID-19 vaccine access, and U.S. lawmakers back global pandemic funding.
- 'God chose me': Congo Ebola survivor finds new purposeon October 1, 2020 at 1:40 pm
For Esperance Nyabintu, catching Ebola was a curse and a gift from God. A year ago the virus killed her husband. Most of her neighbours, friends and family abandoned her, such is the social stigma of ...
- Chaotic presidential debate highlights Covid-19 vaccines & women in DRC accuse Ebola aid workers of sexual abuseon September 30, 2020 at 7:18 am
Rounds newsletter keeps you ahead of the day's health and science news.
- Michigan’s GRAM Inks Covid-19 Vaccine Manufacturing Deal with J&Jon September 29, 2020 at 11:47 am
Grand River Aseptic Manufacturing (GRAM) inked a deal with Janssen Pharmaceutical to support the manufacturing of the Johnson & Johnson company’s Covid-19 vaccine candidate.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- NYC Ebola Doctor Who Trump Blasted 6 Years Ago Fires Back Over Risk of Spreading Viruson October 6, 2020 at 5:13 am
The NYC emergency room physician who survived Ebola in 2014 -- and who then-private citizen Donald Trump blasted for being selfish -- is firing back now that Trump is the president and the one with a ...
- Six years ago, Trump blasted an Ebola-infected doctor. Now he’s hitting back over the president’s coronavirus actions.on October 6, 2020 at 3:49 am
At a time when the president has said that people should not be afraid of an illness that has already killed more than 209,000 Americans, commentators on Monday pointed to his 2014 critique of Spencer ...
- USF researcher using lessons from Ebola in hopes of tracking COVID-19 trajectoryon October 5, 2020 at 8:45 pm
A researcher with the University of South Florida is working to apply methods used to study the Ebola virus outbreaks to look at the spread of the virus causing COVID-19.
- Resurfaced Ebola tweets show that Trump has ignored his own adviceon October 5, 2020 at 2:11 pm
Now Trump’s 2014 tweets about Ebola are casting his pre- and post-diagnosis behavior in what some view as an extremely hypocritical light. In 2014, he repeatedly blamed President Barack Obama for ...
- A Doctor Who’s Fought Ebola And Other Epidemics On Handling The White House Coronavirus Outbreakon October 5, 2020 at 1:16 am
Dr. Mark Kortepeter, who’s fought epidemics on multiple continents, explains what the government needs to do right now to combat the Covid-19 outbreak that’s struck the White House.